Eribulin [ERIB1]

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more lines of systemic anti-cancer treatment where the following criteria have been met:

1. An application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has advanced breast cancer
3. The patient has had at least 2 prior lines of systemic anti-cancer treatment for advanced disease
4. Eribulin is to be otherwise used as set out in its Summary of Product Characteristics

NHS funded From: 21 December 2016

Additional information

Form version: -

CDF Managed Access: NA

NICE Technology Appraisal: TA423 (21 December 2016)

Current Form Version

Note

The data on this page was produced using version 1.381 of the CDF list, downloaded from NHS England’s website on 08 January 2026 at 14:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• ERIB1_prior_to_cdf_1.361
• ERIB1_prior_to_cdf_1.381